Poolbeg Pharma identifies new potential drug candidates for RSV infection

Poolbeg Pharma has identified new potential drug candidates for respiratory syncytial virus (RSV) infection.

The identification of potential RSV treatments emerged from the company’s artificial intelligence (AI) program with partner OneThree Biotech.

The collaboration between the two companies began in February this year, and in November Poolbeg revealed that the AI ​​program had yielded several novel drug targets for the treatment of RSV.

RSV is a respiratory virus that usually causes mild, cold-like symptoms and inflames the smallest airways in the lungs.

According to Poolbeg, it’s one of three major respiratory diseases for which there are no approved vaccines.

Having discovered these drug targets, the companies have now identified several “promising” candidates to advance to a laboratory-based validation phase. This would lead to the companies realizing the full potential of these assets.

This is the first time AI has been used to identify RSV drug candidates.

Poolbeg will now prioritize compounds with existing Phase I safety and tolerability data that, if validated successfully, could be repositioned as novel treatments for RSV infection.

Phase I trials of a new drug are usually the first phases in which people are involved.

Drug candidates are “well positioned” to enter a clinical trial to generate efficacy data for the virus, Poolbeg reported.

“I am pleased that Poolbeg’s unique data set combined with OneThree’s externally validated platform has now delivered new actionable insights into disease biology and drug discovery that can provide much-needed treatment options for both the young and elderly; most susceptible to RSV infection,” said Neel S. Madhukar, CEO of OneThree Biotech.

“Over the past several months, RSV has hospitalized children in the United States and Europe in alarming numbers,” added Jeremy Skillington, Chief Executive of Poolbeg Pharma.

“As pediatric wards are filled beyond capacity and our healthcare systems grapple with a ‘triple disease’ of RSV, influenza and SARS-CoV-2, the need for better treatments has never been more urgent.”

https://www.independent.ie/business/irish/poolbeg-pharma-identifies-new-potential-drug-candidates-for-rsv-infections-42235297.html Poolbeg Pharma identifies new potential drug candidates for RSV infection

Fry Electronics Team

Fry Electronics.com is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@fry-electronics.com. The content will be deleted within 24 hours.

Related Articles

Back to top button